Lv32
250 积分 2023-12-20 加入
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs
4小时前
待确认
Osimertinib in ResectedEGFR-Mutated Non–Small-Cell Lung Cancer
9小时前
已完结
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
5天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
7天前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
19天前
已完结
Cinitapride hydrogen tartrate, a gastrointestinal promotility drug
19天前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
21天前
已完结
Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy
22天前
已完结
Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer
29天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
皖公网安备34019202002308
